On Thursday, Goldman Sachs maintained its Buy rating and $17.00 price target on shares of Roivant Sciences (NASDAQ:ROIV). The firm's positive stance comes after Roivant Sciences announced a significant deal to sell its Dermavant subsidiary to OGN for an estimated $1.2 billion in upfront and future milestone payments, in addition to royalties on future sales of Vtama.
The transaction is structured to provide Roivant with approximately $500 million in the near term, including $175 million at closing, a further $75 million expected upon US approval for atopic dermatitis by the end of the year, and the repayment of credit facilities.
The deal also outlines sales milestones that are contingent on achieving less than or equal to $1 billion in annual net sales. Starting in 2027, Roivant is set to receive tiered royalties beginning in the low single-digits and escalating to 30% on net sales exceeding $1 billion.
Goldman Sachs highlighted that the $1.2 billion deal valuation excludes additional financial benefits from the transfer of debt, which has a carrying value of $286 million, and from cost savings. The firm anticipates that Roivant will continue to concentrate on its clinical pipeline, including IMVT-1402, brepocitinib, and the newly acquired mosliciguat.
Roivant's clinical development is bustling with activity, with multiple late-stage clinical studies expected to release results within the next 12 months. This includes Phase 3 data for batoclimab in myasthenia gravis by FY24, Phase 2b results in CIDP by FY24, Phase 2 findings from a study of namilumab in sarcoidosis by the fourth quarter of 2024, and Phase 3 outcomes from the study of brepocitinib in dermatomyositis during the second half of 2025.
In other recent news, Roivant Sciences has seen significant advancements in its drug portfolio and financial standings. The company reported $18.4 million in product revenue and held a robust $5.7 billion in cash and cash equivalents. H.C. Wainwright and TD Cowen maintained their 'Buy' ratings, while BofA Securities raised its price target to $12.50, maintaining a neutral rating.
Roivant Sciences' crucial developments include a licensing agreement with Organon, which is expected to reduce operating expenses and clear Dermavant's debt from its balance sheet. This deal allows Roivant to concentrate more on its late-stage drug candidates, including IMVT-1402, brepocitinib, and mosliciguat.
Roivant's subsidiary, Pulmovant, has made progress with its Phase 2-ready asset mosliciguat, designed for patients with pulmonary hypertension in interstitial lung disease. The drug demonstrated a 38% reduction in pulmonary vascular resistance.
Further, Roivant's subsidiary, Immunovant (NASDAQ:IMVT), reported positive outcomes from its Phase 2a trial of batoclimab, a treatment for Graves' Disease. A pivotal trial for the treatment is expected to commence by December 31, 2024.
Finally, the company's Annual General Meeting resulted in the re-election of directors and the ratification of Ernst & Young LLP as the company's independent auditor. These are among the recent developments for Roivant Sciences.
InvestingPro Insights
Following the recent strategic moves by Roivant Sciences, including the substantial Dermavant deal, investors and analysts are keeping a close eye on the company's financial health and market performance. According to InvestingPro data, Roivant Sciences boasts a market capitalization of approximately $8.87 billion, which is a testament to its significant presence in the biopharmaceutical sector. Despite challenging market conditions, the company has experienced a robust revenue growth of over 101% in the last twelve months as of Q1 2025, illustrating its ability to expand its financial base amid its clinical developments.
One of the InvestingPro Tips that stands out is the company's strong liquidity position, with liquid assets surpassing short-term obligations, providing Roivant with a cushion to fund its operations and research endeavors. Moreover, the fact that management has been aggressively buying back shares signals a vote of confidence in the company's future prospects and a commitment to enhancing shareholder value.
For investors seeking more in-depth analysis and additional insights, there are over 10 InvestingPro Tips available, which could help in making a more informed decision regarding Roivant Sciences. With a next earnings date scheduled for November 11, 2024, stakeholders will be keen to assess the company's performance and strategic direction moving forward.
While Roivant's gross profit margins have been weak, the company's strategic transactions and pipeline developments may set the stage for a turnaround, as reflected in the fair value estimates by analysts and InvestingPro, which stand at $17 and $12.96 respectively. These valuations suggest a potential upside from the previous close price of $12, aligning with Goldman Sachs' optimistic view on the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.